Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 18Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Astrocytoma 5Oligodendroglioma 4Adenocarcinoma of Lung 4Rectal Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Glioma 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precancerous Conditions 1Pharyngeal Neoplasms 1Paranasal Sinus Neoplasms 1

Interventions

olaparib 1oblimersen 1lutetium Lu 177 dotatate 1Fluorodeoxyglucose F18 1FPP(RGD)2 1Erlotinib Hydrochloride 1Epirubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esthesioneuroblastoma, Olfactory × Erlotinib Hydrochloride × Clear all
NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
66 enrolled
CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡